trending Market Intelligence /marketintelligence/en/news-insights/trending/1hksjr_6lbiqkn-kfxczja2 content esgSubNav
In This List

US FDA issues warning to Bayer over drug manufacturing violations

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


US FDA issues warning to Bayer over drug manufacturing violations

The U.S. Food and Drug Administration issued a warning letter to Bayer AG over violations at its drug manufacturing facility in Leverkusen, Germany, Reuters reported.

The German pharmaceutical company is addressing the concerns raised by the regulator.

Bayer is expecting temporary supply limitations that will affect its blood pressure drug Adalat, blood thinner Aspirin Cardio, antibiotic Avelox and potency drug Levitra.

The company will quantify the impact in its upcoming 2018 guidance on Feb. 28.